Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382834 | 1.00 | CYP1A2 (0.77) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL1045876 | 0.91 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL1050633 | 0.91 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL24486720 | 0.90 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL23055435 | 0.90 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL28662562 | 0.89 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL14584132 | 0.88 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL12787804 | 0.88 | CYP1A2 (0.72) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL14595147 | 0.88 | CYP1A2 (0.72) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL21121979 | 0.87 | CYP1A2 (0.82) | CYP1A2CYP3A4CYP2C9TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981918-B | Modified platinum compound and preparation method and application thereof | 华中科技大学 | 2020-10-16 | — | — | CN | claimed |
| CN-110981918-A | Modified platinum compound and preparation method and application thereof | 华中科技大学 | 2020-04-10 | — | — | CN | claimed |
| CN-104356183-B | Compound having anti-tumor effect as well as preparation method and application thereof | 华中科技大学 | 2017-04-26 | — | — | CN | claimed |
| CN-104356183-A | Compound having anti-tumor effect as well as preparation method and application thereof | UNIV HUAZHONG SCIENCE TECH | 2015-02-18 | — | — | CN | claimed |
| CN-110981918-B | Modified platinum compound and preparation method and application thereof | 华中科技大学 | 2020-10-16 | — | — | CN | disclosed |
| CN-110981918-B | Modified platinum compound and preparation method and application thereof | 华中科技大学 | 2020-10-16 | — | — | CN | disclosed |
| CN-110981918-A | Modified platinum compound and preparation method and application thereof | 华中科技大学 | 2020-04-10 | — | — | CN | disclosed |
| CN-110981918-A | Modified platinum compound and preparation method and application thereof | 华中科技大学 | 2020-04-10 | — | — | CN | disclosed |
| CN-104356183-B | Compound having anti-tumor effect as well as preparation method and application thereof | 华中科技大学 | 2017-04-26 | — | — | CN | disclosed |
| EP-2118048-B1 | MALE CONTRACEPTIVE | AMOBI NNAEMEKA IKECHUKWU (GB) | 2016-11-23 | — | — | EP | disclosed |
| CN-104356183-A | Compound having anti-tumor effect as well as preparation method and application thereof | UNIV HUAZHONG SCIENCE TECH | 2015-02-18 | — | — | CN | disclosed |
| US-8927579-B2 | Male contraceptive | Amobi, Nnaemkea Ikechukwu (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20050272796-A1 | Prevention and treatment of benign prostatic hyperplasia using lonidamine and lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| US-20050272795-A1 | Prevention and treatment of benign prostatic hyperplasia | THRESHOLD PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| US-20050271723-A1 | Dosage forms for treatment of benign prostatic hyperplasia | THRESHOLD PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1592430-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS | Threshold Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040167196-A1 | Treatment of benign prostatic hyperplasia | THRESHOLD PHARMACEUTICALS, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004064735-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064736-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-6001865-A | 3-SUBSTITUTED 1-BENZYL-1H-INDAZOLE DERIVATIVES ANTIFERTILITY AGENT USED TO REDUCE THE POPULATION OF MICE, RATS AND PIGEIONS | ANGELINI PHARMACEUTICALS INC. (US) | 1999-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272795-A1 | Prevention and treatment of benign prostatic hyperplasia | BPHL, LPXN, QDPR | CYP1A2 1175/4885CYP3A4 1278/4885CYP2C9 1747/4885 |
| US-20050272796-A1 | Prevention and treatment of benign prostatic hyperplasia using lonidamine and lonidamine analogs | BPHL, LONP1, LPXN | CYP1A2 1603/4885CYP3A4 1234/4885CYP2C9 1743/4885 |
| US-20040167196-A1 | Treatment of benign prostatic hyperplasia | BPHL, LPXN, QDPR | CYP1A2 1378/4885CYP3A4 1243/4885CYP2C9 2133/4885 |
| US-20050271723-A1 | Dosage forms for treatment of benign prostatic hyperplasia | BPHL, LPXN, LONP1 | CYP1A2 485/4885CYP3A4 490/4885CYP2C9 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.